Prostate cancer is diagnosed by a biopsy in which a sample of body tissue is examined. Sometimes with this technique, cancer can be missed if none of the needles reach the affected tissue, which is known as a false negative. Often it may be necessary to repeat the biopsy if a false negative is suspected.
The main technique for diagnosing prostate cancer is thick-needle fusion biopsy, in which a sample of tissue is removed from the body and viewed under a microscope. The test lasts about 10 minutes and can be done in the doctor's office. Urologists say that in order to reduce the risk of infection, antibiotics are likely to be given before the biopsy and for one or two days after.
What is fusion prostate cancer?
Fusion systems are facilitating the diagnosis of prostate cancer by allowing the fusion of images between MRI and transrectal ultrasound that allow biopsy orientation. Until now, urologists have not been able to effectively use this information when performing this test.
With multi parametric magnetic resonance imaging, images are obtained of the prostate where the areas of the prostate can be seen, to detect where there may be a tumour. These images are then inserted into a tailored ultrasound to mark areas of the prostate that may be affected. Finally, the biopsy is done, in the perineum, avoiding the rectum.
With this technique, the accuracy of the final results is more than doubled, and only two essential punctures are made, directly to the area that may be affected.
Treatment of prostate cancer
The treatment of prostate cancer can kill the disease, though in some cases it can delay the disease, and it may return.
If prostate cancer is left untreated, it can spread through the blood and lymph nodes to other parts of the body, such as the bones, bladder, rectum, liver, lungs, or brain. However, it is estimated that 9 out of 10 patients have localised prostate cancer, i.e. it does not spread.
It is still unknown which is the best treatment for localised prostate cancer; both the diagnosis and the possible treatments depend on many factors. That is why when a man is diagnosed, the condition is evaluated as "low risk" or "initial stage", and the patient goes through an initial period of uncertainty in which he will need information and advice.